US2020316168A1PendingUtilityA1
Inhibitors of igfbp3 binding to tmem219 for treatment of intestinal diseases
Est. expiryJun 4, 2035(~8.9 yrs left)· nominal 20-yr term from priority
A61K 38/1709G01N 2800/065G01N 2800/06G01N 2333/4745G01N 33/6872A61P 1/14A61K 38/177A61P 1/12C07K 16/18A61K 39/395G01N 33/6893C07K 2317/76A61P 43/00A61P 1/04A61P 1/00A61K 45/06
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to an inhibitor of IGFBP3 binding to TMEM219 and uses thereof for the treatment and/or prevention of an intestinal disease in a subject, in particular the treatment and/or prevention of diabetic enteropathy or inflammatory bowel disease.
Claims
exact text as granted — not AI-modified1 . An inhibitor of IGFBP3, wherein the inhibitor is an extracellular fragment of TMEM219, and wherein the inhibitor inhibits or blocks the interaction of IGFBP3 with its receptor TMEM219.
2 .- 4 . (canceled)
5 . The inhibitor of claim 1 , wherein the fragment of TMEM219 is a fragment comprising an extracellular domain of TMEM219 capable of binding IGFBP3.
6 . The inhibitor of claim 5 , wherein the inhibitor is ecto-TMEM219 (SEQ ID NO: 3).
7 .- 9 . (canceled)
10 . A pharmaceutical composition comprising the inhibitor of claim 1 and pharmaceutically acceptable carriers.
11 .- 18 . (canceled)Join the waitlist — get patent alerts
Track US2020316168A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.